0000000000206960

AUTHOR

Jun Huang

showing 5 related works from this author

Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure

2015

Background— Clinical trials in heart failure have focused on the improvement in symptoms or decreases in the risk of death and other cardiovascular events. Little is known about the effect of drugs on the risk of clinical deterioration in surviving patients. Methods and Results— We compared the angiotensin-neprilysin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patients with heart failure and reduced ejection fraction in a double-blind trial. The analyses focused on prespecified measures of nonfatal clinical deterioration. In comparison with the enalapril group, fewer LCZ696-treated patients required intensification of med…

Angiotensin receptorVascular damage Radboud Institute for Health Sciences [Radboudumc 16]receptorsTetrazolesheart failureAngiotensin-Converting Enzyme InhibitorsKaplan-Meier EstimateSacubitrilAngiotensin; Heart failure; Neprilysin; Receptors; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Double-Blind Method; Enalapril; Heart Failure; Humans; Kaplan-Meier Estimate; Natriuretic Peptide Brain; Neprilysin; Peptide Fragments; Risk Factors; Stroke Volume; Survivors; Tetrazoles; Treatment Outcome; Troponin; Disease Progression; Medicine (all); Cardiology and Cardiovascular Medicine; Physiology (medical)AngiotensinEnalaprilRisk FactorsEnalapril/therapeutic useNatriuretic Peptide BrainHeart Failure/bloodSurvivorsReceptorNeprilysinAminobutyrates: Systèmes cardiovasculaire & respiratoire [D03] [Sciences de la santé humaine]Troponin/bloodTroponinAngiotensin Receptor Antagonists/therapeutic useDrug CombinationsAngiotensin-Converting Enzyme Inhibitors/therapeutic useTreatment OutcomeTetrazoles/therapeutic useCardiologyDisease ProgressionValsartanNeprilysinHeart Failure/blood/drug therapy/physiopathologyCardiology and Cardiovascular Medicinemedicine.drugReceptormedicine.medical_specialtyHeart failureneprilysinAngiotensin Receptor Antagonistsreceptors angiotensinDouble-Blind MethodPhysiology (medical)Internal medicineRenin–angiotensin systemmedicineHumansheart failure neprilysin receptors angiotensinEnalaprilbusiness.industryBiphenyl CompoundsStroke Volumemedicine.diseasePeptide FragmentsEndocrinologyAminobutyrates/therapeutic useStroke Volume/physiologyHeart failureNatriuretic Peptide Brain/blood: Cardiovascular & respiratory systems [D03] [Human health sciences]businessNeprilysin/antagonists & inhibitorsPeptide Fragments/bloodSacubitril ValsartanBiomarkersBiomarkers/blood
researchProduct

Internet of Autonomous Vehicles: Architecture, Features, and Socio-Technological Challenges

2019

Mobility is the backbone of urban life and a vital economic factor in the development of the world. Rapid urbanization and the growth of mega-cities is bringing dramatic changes in the capabilities of vehicles. Innovative solutions like autonomy, electrification, and connectivity are on the horizon. How, then, we can provide ubiquitous connectivity to the legacy and autonomous vehicles? This paper seeks to answer this question by combining recent leaps of innovation in network virtualization with remarkable feats of wireless communications. To do so, this paper proposes a novel paradigm called the Internet of autonomous vehicles (IoAV). We begin painting the picture of IoAV by discussing th…

Networking and Internet Architecture (cs.NI)Signal Processing (eess.SP)FOS: Computer and information sciencesbusiness.industryComputer scienceMultitier architectureNetwork virtualization020206 networking & telecommunications02 engineering and technologyEnergy consumptionData scienceComputer Science ApplicationsComputer Science - Networking and Internet ArchitectureComputer Science - Computers and SocietySalientComputers and Society (cs.CY)0202 electrical engineering electronic engineering information engineeringKey (cryptography)FOS: Electrical engineering electronic engineering information engineeringThe InternetElectrical and Electronic EngineeringArchitectureElectrical Engineering and Systems Science - Signal ProcessingbusinessLEAPS
researchProduct

Multi-hop D2D Communications with Network Coding : From A Performance Perspective

2019

Multi-hop device-to-device (D2D) communications play an important role in expanding D2D coverage. In this paper, we study a relay-based and network-coding-assisted (in particular, XOR coding) multi-hop D2D communication system. In the system, toward jointly considering the impact of interference and network traffic conditions on the quality of D2D communications, various channel fading models and traffic models are investigated, and the packet loss probability of D2D links is meticulously computed using these models. With the packet loss probability of D2D links, the general closed-form expressions of end-to-end packet loss probability (E2EPLP) of the system with the presence (or absence) o…

ta213Computer Networks and Communicationsbusiness.industryComputer sciencetraffic modelAerospace Engineeringnetwork codingmatkaviestinverkotCommunications systemperformance evaluationSpread spectrumlangaton tiedonsiirtomobiililaitteetPacket lossLinear network codingAutomotive EngineeringFadingElectrical and Electronic Engineeringbusinessmulti-hop D2D communicationCommunication channelComputer network
researchProduct

Type I Interferon Protects Antiviral CD8+ T Cells from NK Cell Cytotoxicity

2014

Summary Despite development of new antiviral drugs, viral infections are still a major health problem. The most potent antiviral defense mechanism is the innate production of type I interferon (IFN-I), which not only limits virus replication but also promotes antiviral T cell immunity through mechanisms, which remain insufficiently studied. Using the murine lymphocytic choriomeningitis virus model system, we show here that IFN-I signaling on T cells prevented their rapid elimination in vivo. Microarray analyses uncovered that IFN-I triggered the expression of selected inhibitory NK-cell-receptor ligands. Consequently, T cell immunity of IFN-I receptor (IFNAR)-deficient T cells could be rest…

Cytotoxicity ImmunologicImmunologyMedizinReceptor Interferon alpha-betaCD8-Positive T-LymphocytesLymphocytic ChoriomeningitisVirus ReplicationLymphocytic choriomeningitisVirusMiceImmunityInterferonmedicineAnimalsLymphocytic choriomeningitis virusImmunology and AllergyCytotoxic T cellCells CulturedMice KnockoutbiologyPerforinNFIL3medicine.diseaseVirologyImmunity InnateKiller Cells NaturalMice Inbred C57BLBasic-Leucine Zipper Transcription FactorsInfectious DiseasesViral replicationPerforinInterferon Type IImmunologybiology.proteinSignal Transductionmedicine.drugImmunity
researchProduct

The Monoclonal Antitoxin Antibodies (Actoxumab–Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Clostridium diffi…

2016

Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against Clostridium difficile infection (CDI). Standard therapy using antibiotics is associated with a high rate of disease recurrence, highlighting the need for novel treatment strategies that target toxins, the major virulence factors, rather than the organism itself. Human monoclonal antibodies MK-3415A (actoxumab–bezlotoxumab) to C. difficile toxin A and toxin B, as an emerging non-antibiotic approach, significantly reduced the recurrence of CDI in animal models and human clinical trials. Although the main mechanism of protection is through direct neutraliza…

0301 basic medicinelcsh:QR1-502gut microbiomeGut floralcsh:MicrobiologyantibioticsMiceLactobacillusLongitudinal StudiesOriginal Researchbiologyactoxumab and bezlotoxumabMK-3415AAntibodies MonoclonalClostridium difficile3. Good healthAnti-Bacterial AgentsInfectious DiseasesTreatment Outcome16S rDNA amplicon sequencingVancomycinmedicine.drugMicrobiology (medical)030106 microbiologyImmunologyClostridium difficile toxin AColonisation resistanceC. difficile toxin antibodyMicrobiologyMicrobiology03 medical and health sciencesVancomycinClostridium difficile infectionimmune therapymedicineAnimalsClostridioides difficileAkkermansiabiology.organism_classificationAntibodies NeutralizingSurvival AnalysisGastrointestinal MicrobiomeDisease Models Animal030104 developmental biologyBayesian networksBezlotoxumabImmunologyClostridium InfectionsAntitoxinsBroadly Neutralizing AntibodiesFrontiers in Cellular and Infection Microbiology
researchProduct